<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438083</url>
  </required_header>
  <id_info>
    <org_study_id>CRSP-ONC-003</org_study_id>
    <nct_id>NCT04438083</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma</brief_title>
  <official_title>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRISPR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CRISPR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and
      efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study may enroll approximately 95 subjects in total.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">February 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A (dose escalation): Incidence of adverse events</measure>
    <time_frame>From CTX130 infusion up to 28 days post-infusion</time_frame>
    <description>Adverse events defined as dose-limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (cohort expansion): Objective response rate</measure>
    <time_frame>From CTX130 infusion up to 60 months post-infusion]</time_frame>
    <description>Objective response rate per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of CTX130 infusion until date of disease progression or death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of CTX130 until date of death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>CTX130</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion following lymphodepleting chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTX130</intervention_name>
    <description>CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.</description>
    <arm_group_label>CTX130</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abbreviated Inclusion Criteria:

          1. Age ≥18 years and body weight ≥60 kg.

          2. Unresectable or metastatic RCC that has exploited standard of care treatment.

          3. Karnofsky performance status (KPS) ≥80%.

          4. Adequate renal, liver, cardiac, and pulmonary organ function.

          5. Female subjects of childbearing potential and male subjects must agree to use
             acceptable method(s) of contraception from enrollment through at least 12 months after
             CTX130 infusion.

        Abbreviated Exclusion Criteria:

          1. Prior treatment with any anti-CD70 targeting agents.

          2. Prior treatment with any CAR T cells or any other modified T or natural killer (NK)
             cells.

          3. History of certain central nervous system (CNS), cardiac or pulmonary conditions.

          4. Active HIV, hepatitis B virus or hepatitis C virus infection.

          5. Previous or concurrent malignancy, except treated with curative approach not requiring
             systemic therapy and in remission for &gt;12 months, or any other localized malignancy
             with low risk of developing into metastatic disease.

          6. Primary immunodeficiency disorder or active autoimmune disease requiring steroids
             and/or other immunosuppressive therapy.

          7. Prior solid organ transplantation or bone marrow transplant.

          8. Pregnant or breastfeeding females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Will, MD</last_name>
    <role>Study Director</role>
    <affiliation>CRISPR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>+1 (877) 214-4634</phone>
    <email>MedicalAffairs@crisprtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Renal cell carcinoma with clear cell differentiation</keyword>
  <keyword>CRISPR-Cas9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

